<a href="https://www.fiercebiotech.com/medtech/labcorp-raises-full-year-guidance-boosted-its-diagnostics-lab-testing-units" hreflang="en">Labcorp raises full-year guidance, boosted by diagnostics, lab services</a>
Labcorp has raised its full-year 2026 revenue guidance to between $14.65 billion and $14.80 billion, driven by strong demand in its diagnostics and central laboratory services, which contributed to a 5.8% year-over-year sales increase in the first quarter. The company also reported better-than-expected earnings per share, reflecting robust growth across its business segments.
Labcorp's robust growth in its Diagnostics and Biopharma Laboratory Services segments, which has led to an increased full-year revenue guidance for 2026, underscores the rising demand and strategic importance of central laboratory services in the healthtech sector. For professionals tracking investment opportunities or emerging trends, this highlights the potential value in companies focusing on scaling diagnostics and central lab capabilities, particularly with the integration of advanced technologies and services.